Cargando…

DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway

BACKGROUND: DNA methyltransferase 3A (DNMT3A) often mutate on arginine 882 (DNMT3A(R882)) in acute myeloid leukemia (AML). AML patients with DNMT3A R882 mutation are usually resistant to daunorubicin treatment; however, the associated mechanism is still unclear. Therefore, it is urgent to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Xuan, Zhong, Liang, Dan, Wenran, Wang, Xiao, Zhang, Zhonghui, Liu, Zhenyan, Lu, Yang, Shao, Xin, Zhou, Ziwei, Chen, Shuyu, Liu, Beizhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615155/ https://www.ncbi.nlm.nih.gov/pubmed/36303144 http://dx.doi.org/10.1186/s12964-022-00978-1

Ejemplares similares

RIP1-dependent Apoptosis and Differentiation Regulated by Skp2 and Akt/GSK3β in Acute Myeloid Leukemia
por: Dan, Wenran, et al.
Publicado: (2022)

The acute myeloid leukemia variant DNMT3A Arg882His is a DNMT3B-like enzyme
por: Norvil, Allison B, et al.
Publicado: (2020)

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
por: Berenstein, Rimma, et al.
Publicado: (2015)

Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Lin, Jiang, et al.
Publicado: (2011)

Gene expression profiling of the DNMT3A R882 mutation in acute leukemia
por: HUANG, XIANGNAN, et al.
Publicado: (2013)

DNMT3A(R882)-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3A(R882C) OCI-AML3 leukemia cell line
por: Chen, David, et al.
Publicado: (2018)

The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A/R882H complexes
por: Emperle, Max, et al.
Publicado: (2018)

Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells
por: Bera, Rabindranath, et al.
Publicado: (2018)

ZNF460-regulated COMMD7 Promotes Acute Myeloid Leukemia Proliferation Via the NF-κB Signaling Pathway
por: Shao, Xin, et al.
Publicado: (2023)

ZFP91 promotes cell proliferation and inhibits cell apoptosis in AML via inhibiting the proteasome-dependent degradation of RIP1
por: Zhang, Zhonghui, et al.
Publicado: (2022)

Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis
por: Liao, Min, et al.
Publicado: (2021)

The DNMT3A R882H mutant displays altered flanking sequence preferences
por: Emperle, Max, et al.
Publicado: (2018)

Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation
por: Anteneh, Hiwot, et al.
Publicado: (2020)

CRNDE enhances the expression of MCM5 and proliferation in acute myeloid leukemia KG-1a cells by sponging miR-136-5p
por: Liu, Chen, et al.
Publicado: (2021)

GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells
por: Chu, Xuan, et al.
Publicado: (2020)

Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients
por: Yuan, Xiao-Qing, et al.
Publicado: (2019)

DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation
por: Koya, Junji, et al.
Publicado: (2016)

Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns
por: Emperle, Max, et al.
Publicado: (2019)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Expression and prognosis analysis of DNMT family in acute myeloid leukemia
por: Zhang, Ting-Juan, et al.
Publicado: (2020)

Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations
por: Yang, Li, et al.
Publicado: (2019)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
por: Liu, Fu-rong, et al.
Publicado: (2017)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs
por: Yang, Li, et al.
Publicado: (2017)

Understanding the R882H mutation effects of DNA methyltransferase DNMT3A: a combination of molecular dynamics simulations and QM/MM calculations
por: Liu, Lanxuan, et al.
Publicado: (2019)

DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients
por: Yuan, Xiao-Qing, et al.
Publicado: (2016)

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
por: Jawad, Majd, et al.
Publicado: (2022)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Characteristics of DNMT3A mutations in acute myeloid leukemia
por: Park, Dong Jin, et al.
Publicado: (2020)

DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
por: Li, Weijing, et al.
Publicado: (2023)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

882 Risk Factors for Ventilator Associated Events
por: Nuckchady, Dooshanveer, et al.
Publicado: (2014)

Edition Eulenburg No. 882 Suite for Treble Recorder and String Orchestra. A minos

HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling
por: Yang, Shuo, et al.
Publicado: (2019)

TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling
por: Xiao, Yi, et al.
Publicado: (2020)

DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
por: Boulanger, Mathias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ap3q8rqrv3aknd19fk7lt0varv